CliffBio
biologic

regenecyte

HPC, Cord Blood

Loss of exclusivityNovember 2036projected — 12-year biologic exclusivity estimate
CompanyStemCyte →See this company's full patent-cliff portfolio

Drug detail

Brand nameregenecyte
Active ingredientHPC, Cord Blood
Strength>/=1.25x10E6 VIABLE CD34+ CELLS/UNIT IN >/=9x10E8 TNCs/UNIT
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2024
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

regenecyte patent cliff — loss of exclusivity November 2036 | CliffBio